Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | GAA | P10253 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CASP6 | P55212 | 1/20 | 0.55 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15702626 | 0.88 | POLB (0.78) | POLBKMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL20705655 | 0.86 | POLB (0.75) | POLBKMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL19425502 | 0.86 | POLB (0.75) | POLBKMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL5862372 | 0.86 | POLB (0.75) | POLBKMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL7822057 | 0.85 | POLB (0.74) | POLBKMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL19425598 | 0.85 | POLB (0.74) | POLBKMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL728496 | 0.85 | POLB (0.74) | POLBKMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL15702588 | 0.85 | POLB (0.74) | POLBKMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL7814775 | 0.85 | POLB (0.74) | POLBKMT2AMEN1SMN1; SMN2TDP1 | |
| SCHEMBL726935 | 0.85 | POLB (0.74) | POLBKMT2AMEN1SMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3897609-B1 | METHODS OF TREATMENT AND DIAGNOSIS OF TUMOURS | UEA ENTERPRISES LTD (GB) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023209077-A1 | BRIDGED BICYCLIC CARBOXYLIC ACIDS FOR TREATING OSTEOSARCOMA AND EWING SARCOMA | UEA ENTERPRISES LIMITED (GB) | 2023-11-02 | — | — | WO | disclosed |
| WO-2020128534-A1 | METHODS OF TREATMENT AND DIAGNOSIS OF TUMOURS | UEA ENTERPRISES LIMITED (GB) | 2020-06-25 | — | — | WO | disclosed |
| US-10329246-B2 | RUNX2 transcription factor inhibitors and uses thereof | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180086696-A1 | RUNX2 Transcription Factor Inhibitors and Uses Thereof | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086696-A1 | RUNX2 Transcription Factor Inhibitors and Uses Thereof | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086696-A1 | RUNX2 Transcription Factor Inhibitors and Uses Thereof | CBFB, RUNX1, NCOA3 | POLB 2057/4885KMT2A 1149/4885MEN1 1664/4885 |
| US-10329246-B2 | RUNX2 transcription factor inhibitors and uses thereof | CBFB, RUNX1, NCOA3 | POLB 2057/4885KMT2A 1149/4885MEN1 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.